Clinicians perspectives on nutritional supplementation and polycystic ovary syndrome management in women in Indian settings

Manjula S.; Krishna Kumar M.

doi:10.18203/2320-1770.ijrcog20243188

Authors

Manjula S. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India
Krishna Kumar M. Department of Medical Services, Micro Labs Limited, Bangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2320-1770.ijrcog20243188

Keywords:

D-chiro-inositol, Myo-inositol, Nutrition supplementation, Polycystic ovary syndrome

Abstract

Background: Although there were several clinical studies available, there was a dearth of studies among clinicians in actual practice. So, this study seeks to gather expert perspectives on protein supplementation and the management of polycystic ovary syndrome (PCOS) among women, with a special focus on the myo-inositol and D-chiro-inositol combination in Indian settings.

Methods: This cross-sectional study was conducted using a 24-question multi-response questionnaire directed at clinicians. The survey explored practices and opinions on protein supplementation, including frequency, target populations, nutritional status, and timing. It also investigated PCOS prevalence, symptoms, types, treatment recommendations, and dietary adjustments. The perceived effectiveness of myo-inositol and D-chiro-inositol combinations, particularly in conjunction with hormonal therapy and in vitro fertilization (IVF), was assessed. Data were analyzed using descriptive statistics.

Results: Most clinicians (96.59%) identified pregnant or lactating women as the primary group requiring protein supplementation, with 72.73% recommending 26 grams per day. Nearly 95% reported PCOS was commonly diagnosed in women aged 18 to 44 years, and 72% noted that insulin resistance PCOS was more prevalent. Infertility was cited as the main impact of unmanaged PCOS by 67% of respondents. Approximately 43% of clinicians found the myo-inositol and D-chiro-inositol (40:1 ratio) combination to improve PCOS treatment significantly. Additionally, 40% of the experts reported that the supplementation enhances ovarian function, 31% noted improved menstrual cycle regularization, and 77% reported benefits in ovulation, folliculogenesis, and egg quality when combined with IVF.

Conclusions: This study highlighted the importance of protein supplementation for pregnant and lactating women and supports the myo-inositol and D-chiro-inositol combination as a beneficial treatment for PCOS.

Metrics

Metrics Loading ...

References

Alotaibi AF, Khdary SN, Alzarzor Alajami MA, Sambas EA, Aldakhil NA, Naibulharam DY, et al. Pattern of dietary supplement use and its psychosocial predictors among females visiting fitness centers in Saudi Arabia: Findings from a cross-sectional study. Saudi Pharm J. 2024;32(3):101966.

Chea N, Tegene Y, Astatkie A, Spigt M. Prevalence of undernutrition among pregnant women and its differences across relevant subgroups in rural Ethiopia: a community-based cross-sectional study. J Health Popul Nutr. 2023;42:17.

Malnutrition among Women. Available from: https://pib.gov.in/newsite/PrintRelease.aspx?relid=200142. Accessed on 23 July 2024.

Feskens EJM, Bailey R, Bhutta Z, Biesalski HK, Eicher-Miller H, Krämer K, et al. Women’s health: optimal nutrition throughout the lifecycle. Eur J Nutr. 2022;61(Suppl 1):1-23.

WHO. High-protein supplementation during pregnancy. Available from: https://www.who.int/tools/elena/ interventions/high-protein-pregnancy. Accessed on 23 July 2024.

Barros FC, Bhutta ZA, Batra M, Hansen TN, Victora CG, Rubens CE, et al. Global report on preterm birth and stillbirth (3 of 7): evidence for effectiveness of interventions. BMC Pregnancy Childbirth. 2010;10(Suppl 1):S3.

Bhutta ZA, Ahmed T, Black RE, Cousens S, Dewey K, Giugliani E, et al. What works? Interventions for maternal and child undernutrition and survival. Lancet. 2008;371(9610):417-40.

Liberato SC, Singh G, Mulholland K. Effects of protein energy supplementation during pregnancy on fetal growth: a review of the literature focusing on contextual factors. Food Nutr Res. 2013;57:24235913.

WHO. Polycystic ovary syndrome. Available from: https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome. Accessed on 23 July 2024.

Kiani AK, Donato K, Dhuli K, Stuppia L, Bertelli M. Dietary supplements for polycystic ovary syndrome. J Prev Med Hyg. 2022;63(2 Suppl 3):E206-13.

Madnani N, Khan K, Chauhan P, Parmar G. Polycystic ovarian syndrome. Indian J Dermatol Venereol Leprol. 2013;79:310.

Bulsara J, Patel P, Soni A, Acharya S. A review: brief insight into polycystic ovarian syndrome. Endocr Metab Sci. 2021;3:100085.

Jabeen A, Yamini V, Rahman Amberina A, Dinesh Eshwar M, Vadakedath S, Begum GS, et al. Polycystic ovarian syndrome: prevalence, predisposing factors, and awareness among adolescent and young girls of south India. Cureus. 2022;14(8):e27943.

Jungari M, Choudhary A, Gill NK. Comprehensive management of polycystic ovary syndrome: effect of pharmacotherapy, lifestyle modification, and enhanced adherence counselling. Cureus. 2023;15(2):e35415.

Teede HJ, Misso ML, Costello MF, Dokras A, Laven J, Moran L, et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertil Steril. 2018;110(3):364-79.

Roseff S, Montenegro M. Inositol treatment for PCOS should be science-based and not arbitrary. Int J Endocrinol. 2020;2020(1):6461254.

Unfer V, Porcaro G. Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome. Expert Rev Clin Pharmacol. 2014;7(5):623-31.

Ota E, Hori H, Mori R, Tobe-Gai R, Farrar D. Antenatal dietary education and supplementation to increase energy and protein intake. Cochrane Database Syst Rev. 2015;(6):CD000032.

Picciano MF. Pregnancy and lactation: physiological adjustments, nutritional requirements and the role of dietary supplements. J Nutr. 2003;133(6):1997S-2002S.

Trumbo P, Schlicker S, Yates AA, Poos M. Dietary reference intakes for energy, carbohydrate, fiber, fat, fatty acids, cholesterol, protein and amino acids. (Commentary). J Am Dietetic Assoc. 2002;102(11):1621-31.

Murphy MM, Higgins KA, Bi X, Barraj LM. Adequacy and sources of protein intake among pregnant women in the United States, NHANES 2003-2012. Nutrients. 2021;13(3):795.

Kominiarek MA, Rajan P. Nutrition Recommendations in Pregnancy and Lactation. Med Clin North Am. 2016;100(6):1199-215.

Azziz R, Sanchez LA, Knochenhauer ES, Moran C, Lazenby J, Stephens KC, et al. Androgen excess in women: experience with over 1000 consecutive patients. J Clin Endocrinol Metab. 2004;89(2):453-62.

Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev. 2015;36(5):487-525.

Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: Guide to the Best Practices in the Evaluation and Treatment of Polycystic Ovary Syndrome- Part 1. Endocr Pract. 2015;21(11):1291-300.

DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril. 2005;83(5):1454-60.

Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219-31.

Boomsma CM, Eijkemans MJ, Hughes EG, Visser GH, Fauser BC, Macklon NS. A meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Hum Reprod Update. 2006;12(6):673-83.

Kicińska AM, Maksym RB, Zabielska-Kaczorowska MA, Stachowska A, Babińska A. Immunological and metabolic causes of infertility in polycystic ovary syndrome. Biomedicines. 2023;11(6):1567.

March WA, Moore VM, Willson KJ, Phillips DIW, Norman RJ, Davies MJ. The prevalence of polycystic ovary syndrome in a community sample assessed under contrasting diagnostic criteria. Hum Reprod. 2010;25(2):544-51.

Monastra G, Vazquez-Levin M, Bezerra Espinola MS, Bilotta G, Laganà AS, Unfer V. D-chiro-inositol, an aromatase down-modulator, increases androgens and reduces estrogens in male volunteers: a pilot study. Basic Clin Androl. 2021;31(1):13.

Nordio M, Basciani S, Camajani E. The 40:1 myo-inositol/D-chiro-inositol plasma ratio is able to restore ovulation in PCOS patients: comparison with other ratios. Eur Rev Med Pharmacol Sci. 2019;23(12):5512-21.

Pustotina O, Myers SH, Unfer V, Rasulova I. The effects of myo-inositol and d-chiro-inositol in a ratio 40:1 on hormonal and metabolic profile in women with polycystic ovary syndrome classified as phenotype A by the Rotterdam Criteria and EMS-Type 1 by the EGOI Criteria. Gynecol Obstet Investig. 2024;89(2):131-9.

Kalra B, Kalra S, Sharma JB. The inositols and polycystic ovary syndrome. Indian J Endocrinol Metab. 2016;20(5):720-4.

Benelli E, Del Ghianda S, Di Cosmo C, Tonacchera M. A Combined therapy with myo-inositol and D-chiro-inositol improves endocrine parameters and insulin resistance in PCOS young overweight women. Int J Endocrinol. 2016;2016:3204083.

Colazingari S, Treglia M, Najjar R, Bevilacqua A. The combined therapy myo-inositol plus D-chiro-inositol, rather than D-chiro-inositol, is able to improve IVF outcomes: results from a randomized controlled trial. Arch Gynecol Obstet. 2013;288(6):1405-11.

Mohammadi S, Eini F, Bazarganipour F, Taghavi SA, Kutenaee MA. The effect of myo-inositol on fertility rates in poor ovarian responder in women undergoing assisted reproductive technique: a randomized clinical trial. Reprod Biol Endocrinol. 2021;19:61.

Zheng X, Lin D, Zhang Y, Lin Y, Song J, Li S, et al. Inositol supplement improves clinical pregnancy rate in infertile women undergoing ovulation induction for ICSI or IVF-ET. Medicine. 2017;96(49):e8842.

Merviel P, James P, Bouée S, Le Guillou M, Rince C, Nachtergaele C, et al. Impact of myo-inositol treatment in women with polycystic ovary syndrome in assisted reproductive technologies. Reprod Health. 2021;18(1):13.

Mendoza N, Diaz-Ropero MP, Aragon M, Maldonado V, Llaneza P, Lorente J, et al. Comparison of the effect of two combinations of myo-inositol and D-chiro-inositol in women with polycystic ovary syndrome undergoing ICSI: a randomized controlled trial. Gynecol Endocrinol. 2019;35(8):695-700.